

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Innovent

信達生物製藥

**INNOVENT BIOLOGICS, INC.**

*(Incorporated in the Cayman Islands with Limited Liability)*

**(Stock Code: 1801)**

## **INSIDE INFORMATION ANNOUNCEMENT UPDATE ON THE COMPANY’S PRODUCT REVENUE IN THE FOURTH QUARTER OF 2023**

This announcement is made by Innovent Biologics, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

In the fourth quarter of 2023, the Company achieved a total product revenue exceeding RMB1.6 billion, representing a robust year-over-year growth of over 65%, along with continuous efforts in enhancing productivity and efficiency under a healthy and sustainable operation model. During the quarter, TYVYT<sup>®</sup> (sintilimab injection) continued its strong sales performance and solid market-leading position propelled by its broad indications and National Reimbursement Drug List (“**NRDL**”) coverage. Besides, the Company’s other products also continued rapid ramp-up growth.

Meanwhile, as part of a strategic plan, we have been steadily establishing commercialization in the cardiovascular and metabolism (“**CVM**”) field during the quarter. The Company plans to build a compelling portfolio and brand franchise in both oncology and non-oncology (including CVM, autoimmune, ophthalmology) areas, aiming for a long-term growth of the Company.

During the quarter, the seventh indication of TYVYT<sup>®</sup> (sintilimab injection) and the eighth indication of BYVASDA<sup>®</sup> (bevacizumab injection) were newly included into the NRDL (2023 Version), making them the only PD-1 inhibitor and the only bevacizumab approved and included in the NRDL for the treatment of non-small cell lung cancer (“**NSCLC**”) post EGFR-TKI therapy in China. The updated NRDL officially went into effect on January 1, 2024, further increasing the accessibility of these drugs for patients. A new indication for olverembatinib was approved, allowing more patients with chronic myeloid leukemia (“**CML**”) to benefit from the drug. Furthermore, new drug applications (“**NDA**”) of two innovative oncology drugs – IBI-344 (ROS1 inhibitor, taletrectinib) and IBI-351 (KRAS G12C inhibitor) - were accepted and granted priority review designation by the National Medical Products Administration (“**NMPA**”) of China, which would add two new products to our diversified commercial portfolio once approved.

The Company has built a robust pipeline of over 30 valuable assets in the fields of oncology, CVM, autoimmune, ophthalmology diseases and other major therapeutic areas. As of now, the Company has ten approved products, two assets under the NMPA review, five assets in Phase III or pivotal clinical trials, and approximately 20 additional molecules in clinical studies. The Company believes that its robust and innovative pipeline with the broad market potential of its products, provide a solid foundation for the Company's long-term sustainable growth.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board  
**Innovent Biologics, Inc.**  
**Dr. De-Chao Michael Yu**  
*Chairman and Executive Director*

Hong Kong, China,  
February 06, 2024

*As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede as Executive Director, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Dr. Kaixian Chen and Mr. Gary Zieziula as Independent Non-executive Directors.*